Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24858849 | 0.84 | MAOA (0.46) | ALDH1A1MAPTMAOACA1CA2 | |
| SCHEMBL25137220 | 0.76 | MAOA (0.35) | ALDH1A1MAPTMAOACA1CA2 | |
| SCHEMBL628362 | 0.76 | MAOA (0.64) | ALDH1A1MAPTPKMMAOAMEN1 | |
| SCHEMBL20041448 | 0.73 | GAA (0.40) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL25137444 | 0.70 | MAOA (0.35) | ALDH1A1MAPTPKMMAOAMEN1 | |
| SCHEMBL24858842 | 0.70 | GAA (0.32) | MAOAMEN1KMT2A | |
| SCHEMBL762766 | 0.69 | MAOA (0.68) | ALDH1A1MAPTPKMMAOAMEN1 | |
| SCHEMBL25137472 | 0.69 | ALDH1A1 (0.45) | ALDH1A1MAPTMAOAMEN1POLB | |
| SCHEMBL16079012 | 0.68 | ALDH1A1 (0.37) | ALDH1A1MAPTPKM | |
| SCHEMBL24858858 | 0.65 | MGLL (0.37) | ALDH1A1MAPTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275169-A1 | Combination Therapies for Enhancing Protein Degradation | HSPA2, HSPBP1, HSPH1 | ALDH1A1 2288/4885MAPT 27/4885PKM 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.